Towards gene-editing treatment for alzheimer's disease: ApoE4 allele-specific knockout using a CRISPR cas9 variant

Background: The apolipoprotein E4 (ApoE4) is known as the most prevalent genetic risk factor for sporadic Alzheimer's disease (AD). More than 60% of these patients express the ApoE4 protein. This protein increases the risk of r AD by lowering the age of onset of the disease by as much as 10–20 years. Eliminating the expression of ApoE4 may prevent the development of this pathology.